GASTROESOPHAGEAL-JUNCTION CANCER
Clinical trials for GASTROESOPHAGEAL-JUNCTION CANCER explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL-JUNCTION CANCER trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL-JUNCTION CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug enters first human trials for multiple tumor types
Disease control OngoingThis is the first human study testing the safety and early effects of an experimental drug called BL-M17D1 in people with advanced cancers that have a specific marker called HER2. The trial will enroll 120 adults with various hard-to-treat cancers, including breast, lung, and sto…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo tested in fight against advanced stomach cancer
Disease control OngoingThis study is testing a new drug called bemarituzumab, given in combination with other cancer therapies, for people with previously untreated advanced stomach or gastroesophageal junction cancer. The main goals are to see if the combinations are safe and if they can shrink tumors…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
Two-Pronged attack: experimental drug aims to Re-Engage immune system against tough cancers
Disease control OngoingThis early-stage study is testing a new drug called AZD7789 in people with advanced lung or stomach cancers that have spread and stopped responding to standard immunotherapy. The main goals are to find a safe dose and see if the drug shows any signs of shrinking tumors. The drug …
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New engineered immune cell therapy enters human testing for tough digestive cancers
Disease control OngoingThis is an early-stage study testing the safety and optimal dose of a new treatment called LB1908, a type of CAR-T cell therapy, for adults with advanced cancers of the stomach, esophagus, or pancreas. The therapy involves collecting a patient's own immune cells, engineering them…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New drug combo aims to stop deadly esophageal cancer from coming back
Disease control OngoingThis study tests whether a combination of two drugs (trastuzumab deruxtecan and nivolumab) given for one year after surgery can help prevent cancer from returning in patients with HER2-positive esophageal or gastroesophageal junction cancer. The treatment is for patients who have…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE2 • Sponsor: Brown University • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC
-
New hope for tough cancers: first human test of experimental drug begins
Disease control OngoingThis early-stage trial is testing a new drug called TST001 for people with advanced stomach, gastroesophageal junction, or pancreatic cancer. The main goals are to find a safe dose and see how well the body handles the drug, both alone and when combined with other standard cancer…
Matched conditions: GASTROESOPHAGEAL-JUNCTION CANCER
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated Mar 02, 2026 15:23 UTC